Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using BLA-identical sibling donors in myelodysplastic syndromes

被引:268
作者
Martino, Rodrigo
Iacobelli, Simona
Brand, Ronald
Jansen, Thekla
van Biezen, Anja
Finke, Jurgen
Bacigalupo, Andrea
Beelen, Dietrich
Reiffers, Jossy
Devergie, Agnes
Alessandrino, Emilie
Mufti, Ghulam J.
Barge, Renee
Sierra, Jorge
Ruutu, Tapani
Boogaerts, Marc
Falda, Michele
Jouet, Jean-Pierre
Niederwieser, Dieter
de Witte, Theo
机构
[1] Autonomous Univ Barcelona, Hosp Santa Cruz & San Pablo, Serv Hematol Clin, Div Clin Hematol, E-08025 Barcelona, Spain
[2] Leiden Univ, Dept Med Stat, NL-2300 RA Leiden, Netherlands
[3] Chron Leukemia Working Party Registry, NL-2300 RA Leiden, Netherlands
[4] Univ Freiburg, Dept Med Hematol & Oncol, D-7800 Freiburg, Germany
[5] Osped San Martino Genova, Dept Hematol, Genoa, Italy
[6] Univ Hosp, Dept Bone Marrow Transplantat, Essen, Germany
[7] CHU Bordeaux, Hosp Haut Leveque, Pessac, France
[8] Hop St Louis, Dept Hematol, F-75010 Paris, France
[9] Kings Coll London, Sch Med, Dept Hematol, London, England
[10] Policlin San Matteo, IRCCS, Pavia, Italy
[11] Leiden Univ, Dept Hematol, Med Ctr, NL-2300 RA Leiden, Netherlands
[12] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland
[13] Univ Hosp Louvain, Dept Hematol, Louvain, Belgium
[14] Azienda Osped S Giovanni, Ctr Trapianti Midollo, Turin, Italy
[15] Hop Claude Huriez, Serv Malad Sang, Lille, France
[16] Univ Hosp Leipzig, Dept Internal Med, Leipzig, Germany
[17] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Nijmegen, Netherlands
关键词
D O I
10.1182/blood-2005-11-4503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MIDS) who underwent transplantation with a human leukocyte antigen (HLA)-identical sibling donor were analyzed according to 2 types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloalblative (or high-dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (hazard ratio [HR], 1.64; 95% confidence interval [95% CI], 1.2-2.2; P =.001), but the 3-year nonrelapse mortality (NIRM) rate was decreased in the RIC group (HR, 0.61; 95% Cl, 0.41-0.91; P =.015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SIMC vs 33% in RIC;. multivariate P =.9; and 45% vs 41 %, respectively; P =.8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age > 50 years in 73% RIC vs 28% in SMC, P <.001) and had more adverse pretransplantation variables. However, based on the higher risk of relapse, patients with no contraindications for SIMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MIDS.
引用
收藏
页码:836 / 846
页数:11
相关论文
共 39 条
  • [1] Bone marrow transplantation for myelodysplasia
    Anderson, JE
    [J]. BLOOD REVIEWS, 2000, 14 (02) : 63 - 77
  • [2] Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia
    Anderson, JE
    Anasetti, C
    Appelbaum, FR
    Schoch, G
    Gooley, TA
    Hansen, JA
    Buckner, CD
    Sanders, JE
    Sullivan, KM
    Storb, R
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (01) : 59 - 67
  • [3] Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
    Andersson, BS
    Gajewski, J
    Donato, M
    Giralt, S
    Gian, V
    Wingard, J
    Tarantolo, S
    Fernandez, H
    Hu, WW
    Blume, K
    Kashyap, A
    Forman, SJ
    Champlin, RE
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (Suppl 2) : S35 - S38
  • [4] Immunobiologic therapies for myelodysplastic syndrome
    Appelbaum, FR
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2004, 17 (04) : 653 - 661
  • [5] Appelbaum FR, 1998, LEUKEMIA, V12, pS25
  • [6] Comorbidity and beyond: pre-transplant clinical assessment
    Artz, AS
    [J]. BONE MARROW TRANSPLANTATION, 2005, 36 (06) : 473 - 474
  • [7] Bacigalupo A, 2000, BRIT J HAEMATOL, V108, P99
  • [8] Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
    Bibawi, S
    Abi-Said, D
    Fayad, L
    Anderlini, P
    Ueno, NT
    Mehra, R
    Khouri, I
    Giralt, S
    Gajewski, J
    Donato, M
    Claxton, D
    Braunschweig, I
    van Besien, K
    Andreeff, M
    Andersson, BS
    Estey, EH
    Champlin, R
    Przepiorka, D
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2001, 67 (04) : 227 - 233
  • [9] Casper J., 2004, Annals of Hematology, V83, pS70
  • [10] Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
    Chakraverty, R
    Peggs, K
    Chopra, R
    Milligan, DW
    Kottaridis, PD
    Verfuerth, S
    Geary, J
    Thuraisundaram, D
    Branson, K
    Chakrabarti, S
    Mahendra, P
    Craddock, C
    Parker, A
    Hunter, A
    Hale, G
    Waldmann, H
    Williams, CD
    Yong, K
    Linch, DC
    Goldstone, AH
    Mackinnon, S
    [J]. BLOOD, 2002, 99 (03) : 1071 - 1078